---
run_id: halo-evidence-vs-diagnosis-validation-v8-generic-advice-prompted-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: generic_advice_prompted
run_number: 5
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 505
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
condition_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
output_file: model-outputs/generic_advice_prompted-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `generic_advice_prompted`, run 5 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 505, on the frozen condition packet.

## Output

I recommend that you advise the CEO to commit to the **targeted evidence pass.**

### Reasoning
You are currently facing a classic "False Positive" scenario. The upbeat board narrative is being driven by lagging indicators (revenue from discounts) and vanity metrics (aggregate usage), while the leading indicators (front-line retention and auditor rejection) are flashing red.

Here is the breakdown of the tradeoffs:

**1. The Danger of Scaling Broadly (Option 1):**
Scaling now would be a catastrophic mistake. Your revenue growth is artificial—72% of it is tied to temporary discounts and early renewals. This is not "Product-Market Fit"; it is "Discount-Market Fit." If you scale quota and implementation hires based on this signal, you are scaling a leaky bucket. When the six-month discounts expire and the "non-renewal letters" finally hit the books, you will have a bloated cost structure and a churn crisis that you cannot fix with more sales hires.

**2. The Danger of Narrowing Focus (Option 3):**
While the insurance segment’s failure regarding "auditor explainability" is a critical insight, pivoting the entire company strategy based on one segment's failure is premature. You don't yet know if the "broad" market actually likes the tool or if they are also just enjoying the discounts. Narrowing the focus now might solve the audit problem but could accidentally kill a viable broader market wedge.

**3. The Necessity of the Evidence Pass (Option 2):**
This is the only option that treats the current situation as a hypothesis rather than a victory. By pausing discounts and instrumenting reviewer-level behavior, you decouple "sales success" from "product success."
*   **The "Champion" Trap:** Your 44% usage increase is a mirage caused by a few power users. You need to know if the *front-line reviewer* (the actual user) finds value. If only 31% return after week one, the product is currently a "toy" for managers, not a "tool" for workers.
*   **The Support Mask:** Reclassifying product issues as "training questions" is a dangerous internal behavior that hides the product's friction. An evidence pass forces these issues back into the light.

### The Strongest Reason Against This Recommendation
**The "Momentum" Risk.**
The board is currently euphoric. The CEO is likely feeling the wind at their back. Recommending a "pause" to collect evidence will be perceived by Sales leadership and potentially the CEO as "product hesitation" or "over-analysis paralysis." You are effectively asking the CEO to tell the board, "The story we just told you is potentially misleading, and we need to slow down to make sure we aren't lying to ourselves." This creates significant political friction and risks the CEO ignoring you to maintain the current narrative.

### Evidence That Would Change My Mind
I would move from the "Evidence Pass" to "Scale Broadly" only if you could produce data showing that **front-line reviewer retention (the 31%) is increasing organically** across multiple segments, independent of the discount-driven renewals.

If the users who *didn't* get the "strategic-feature pitch" are still adopting the tool and staying active after 30 days, it proves the value proposition is intrinsic and the "wedge" is real. Until that specific metric moves, the revenue growth is a financial artifact, not a product victory.
